Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2018

View Archived Issues

siRNA prevents pre-eclampsia in mice and primates

Anti-Andean antibodies protect postexposure

Imiquimod analogue fights more strains of Leishmania

Lung specificity means low tox for inhalable JAK inhibitor

Presepsin is a prognostic marker in congenital heart disease

Phase I results for PIN-201104 support progression to phase II for asthma

First dosing in phase Ib study of EDP-1815 in psoriasis and atopic dermatitis

miR-21 predicts functional worsening in children with CHD-associated pulmonary hypertension

European Commission approves Poteligeo for mycosis fungoides and Sezary syndrome

FDA grants accelerated approval to Vitrakvi for advanced solid tumors with NTRK gene fusion

HBV capsid assembly inhibitors discovered at Shanghai Longwood Biopharmaceuticals

Sanford Burnham Prebys Medical Discovery Institute identifies ACP1 inhibitors

REVOLUTION Medicines synthesizes rapamycin analogues

Cyclin-dependent kinase inhibitors patented by Selection Bioscience

Gene methylation of nontumoral liver tissue predicts recurrence of HCC after surgical resection

BAT-8001, a potent anti-HER2 antibody-drug conjugate, shows promising preclinical profile

Phase I study demonstrates bioequivalence of CT-P16 with the reference bevacizumab products

Aurigene presents AU-15330, a novel dual degrader of SMARCA2/4

G1 Therapeutics reports topline data from second phase II trial of trilaciclib in first-line SCLC

Belgian clearances for phase I trial of anti-IL-7 receptor antagonist OSE-127

Janssen initiates phase I study of live biotherapeutic product VE-202 for IBD

European Commission approves pegfilgrastim biosimilar Ziextenzo

FDA clears IND for phase I trial of AVID-200 in solid tumors

Vivace Therapeutics identifies YAP1/TEAD interaction inhibitors

New BTK inhibitors developed at the Korea Research Institute of Chemical Technology

Cortexyme patents gingipain R1/R2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...